We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News: Santen Pharmaceutical Co., Ltd. (“Santen”) and Novagali Pharma SA (“Novagali”) announced today the success of the simplified cash tender offer for the...
Regulatory News: Novagali Pharma (Paris:NOVA), a pharmaceutical company that develops and markets innovative ophthalmic products, today announces its revenue for the first...
Regulatory News: Following the press release of September 28, 2011, in accordance with articles 223-2 and 223-6 of the general regulations of the French Autorité des...
Regulatory News: Santen Pharmaceutical Co., Ltd. (Osaka, Ticker Code 4536JP) (hereafter “Santen”), a leading Japanese pharmaceutical company, and Novagali Pharma S.A...
Regulatory News: Novagali Pharma (Paris:NOVA) announced today US phase II positive results on the efficacy and safety of Catioprost® in patients with glaucoma and...
Regulatory News: Novagali Pharma (Paris:NOVA), a pharmaceutical company that develops and markets innovative ophthalmic products, informs its shareholders and the financial...
Regulatory News: Novagali Pharma (Paris:NOVA), a pharmaceutical company that develops and markets innovative ophthalmic products, today announces its half-year results1 to...
Regulatory News: Novagali (Paris:NOVA): Novagali Pharma, a pharmaceutical company that develops and sells innovative ophthalmic products, today announces its revenue for...
Regulatory News: Approval of all the resolutions proposed at the Combined General Meeting of the shareholders on June 22, 2011 Novagali Pharma (Paris:NOVA), a...
Regulatory News: Novagali Pharma (Paris:NOVA), a pharmaceutical company that develops innovative ophthalmic products, can today announce that it has signed an exclusive...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions